title: Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
abstract: Vismodegib is proven to be effective in the treatment of locally advanced and metastatic basal cell carcinoma, but evidence of resistance is beginning to emerge. A case of advanced recurrent periocular basal cell carcinoma which responded dramatically to vismodegib after 3 months but recurred after 9 months due to drug resistance, eventually requiring orbital exenteration, is presented. The mechanism of vismodegib resistance is discussed.
authors.affiliation: Adnexal Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom.
authors.forename: Vasilios P
authors.initials: VP
authors.lastname: Papastefanou
authors.forename: Cornelius
authors.initials: C
authors.lastname: René
mesh_terms: D000369:Aged, 80 and over; D000813:Anilides / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000175:diagnosis / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D009918:Orbital Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D011725:Pyridines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
chemical_list: D000813:Anilides; C538724:HhAntag691; D011725:Pyridines